Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
42.56
-1.09 (-2.50%)
Nov 21, 2024, 4:00 PM EST - Market closed
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Avidity Biosciences stock have an average target of 63.22, with a low estimate of 45 and a high estimate of 96. The average target predicts an increase of 48.54% from the current stock price of 42.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RNA stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +52.73% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +40.98% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +40.98% | Oct 31, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 → $65 | Strong Buy | Maintains | $60 → $65 | +52.73% | Oct 30, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $56 → $78 | Strong Buy | Maintains | $56 → $78 | +83.27% | Oct 21, 2024 |
Financial Forecast
Revenue This Year
11.41M
from 9.56M
Increased by 19.33%
Revenue Next Year
12.59M
from 11.41M
Increased by 10.35%
EPS This Year
-2.85
from -2.91
EPS Next Year
-3.12
from -2.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.1M | 35.1M | 263.2M | ||
| Avg | 11.4M | 12.6M | 67.2M | ||
| Low | n/a | n/a | 9.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 130.6% | 207.4% | 1,990.3% | ||
| Avg | 19.3% | 10.4% | 433.4% | ||
| Low | - | - | -22.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.55 | -2.26 | -1.25 | ||
| Avg | -2.85 | -3.12 | -3.37 | ||
| Low | -3.30 | -4.16 | -4.12 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.